News Headlines Article

Big Pharma Gets Solace From Europe
The Wall Street Journal

Are the transatlantic tables turning in pharma?

Switzerland’s Novartis said this past week that it was seeing faster uptake of heart-failure drug Entresto in Europe than in the U.S. The potential blockbuster has struggled: It sold just $17 million in the first quarter, with Novartis guiding to $200 million for the year, well below forecasts.

With heightened focus on the burden of high U.S. drug prices, Novartis said it got a better reception in Europe’s single-payer system than in the U.S. for its value-for-money pitch for Entresto, which helps to reduce hospitalizations.

Commands